WO2011126576A3 - Genetic signatures in the envelope glycoprotein of hiv-1 - Google Patents

Genetic signatures in the envelope glycoprotein of hiv-1 Download PDF

Info

Publication number
WO2011126576A3
WO2011126576A3 PCT/US2011/000642 US2011000642W WO2011126576A3 WO 2011126576 A3 WO2011126576 A3 WO 2011126576A3 US 2011000642 W US2011000642 W US 2011000642W WO 2011126576 A3 WO2011126576 A3 WO 2011126576A3
Authority
WO
WIPO (PCT)
Prior art keywords
hiv
envelope glycoprotein
genetic signatures
signatures
genetic
Prior art date
Application number
PCT/US2011/000642
Other languages
French (fr)
Other versions
WO2011126576A2 (en
Inventor
Barton F. Haynes
David C. Montefiori
Hua-Xin Liao
Feng Gao
Bette K. Korber
S. Gnanakaran
Marcus G. Daniels
Tanmoy Bhattacharya
Alan S. Lapedes
Original Assignee
Duke University
Los Alamos National Security, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Duke University, Los Alamos National Security, Llc filed Critical Duke University
Publication of WO2011126576A2 publication Critical patent/WO2011126576A2/en
Publication of WO2011126576A3 publication Critical patent/WO2011126576A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16023—Virus like particles [VLP]

Abstract

The present invention relates, in general, to HIV-1 and, in particular, to immunogens that elicit broadly neutralizing antibodies against HIV-1, and compositions comprising same. The invention further relates to methods of inducing the production of such antibodies in a subject.
PCT/US2011/000642 2010-04-09 2011-04-11 Genetic signatures in the envelope glycoprotein of hiv-1 WO2011126576A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32266310P 2010-04-09 2010-04-09
US61/322,663 2010-04-09

Publications (2)

Publication Number Publication Date
WO2011126576A2 WO2011126576A2 (en) 2011-10-13
WO2011126576A3 true WO2011126576A3 (en) 2012-02-23

Family

ID=44763453

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/000642 WO2011126576A2 (en) 2010-04-09 2011-04-11 Genetic signatures in the envelope glycoprotein of hiv-1

Country Status (1)

Country Link
WO (1) WO2011126576A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102011105660A1 (en) * 2011-06-22 2012-12-27 TriOpto Tec GmbH Use of 10H-benzo [g] pteridine-2,4-dione derivatives

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030215793A1 (en) * 2002-01-17 2003-11-20 Hahn Beatrice H. Complete genome sequence of a simian immunodeficiency virus from a wild chimpanzee
US20040052821A1 (en) * 1996-07-08 2004-03-18 Genentech, Inc. HIV envelope polypeptides and vaccine
US20060014148A1 (en) * 2002-07-23 2006-01-19 Barton Haynes Igg fc/hiv-gp120/c3d fusion protien
WO2008118470A2 (en) * 2007-03-27 2008-10-02 The Regents Of The University Of California Acute transmitted hiv envelope signatures

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040052821A1 (en) * 1996-07-08 2004-03-18 Genentech, Inc. HIV envelope polypeptides and vaccine
US20030215793A1 (en) * 2002-01-17 2003-11-20 Hahn Beatrice H. Complete genome sequence of a simian immunodeficiency virus from a wild chimpanzee
US20060014148A1 (en) * 2002-07-23 2006-01-19 Barton Haynes Igg fc/hiv-gp120/c3d fusion protien
WO2008118470A2 (en) * 2007-03-27 2008-10-02 The Regents Of The University Of California Acute transmitted hiv envelope signatures

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GNANAKARAN, S. ET AL.: "Genetic signatures in the envelope glycoproteins of HIV-1 that associate with broadly neutralizing antibodies.", PLOS COMPUTATIONAL BIOLOGY, vol. 6, no. ISS.10, 7 October 2010 (2010-10-07), pages E1000955,2,14,19 *
KULKARNI, S.S. ET AL.: "Highly complex neutralization determinants on a monophyletic lineage of newly transmitted subtype C HIV-1 Env clones from India.", VIROLOGY, vol. 385, no. ISS.2, 23 January 2009 (2009-01-23), pages 505 - 520 *

Also Published As

Publication number Publication date
WO2011126576A2 (en) 2011-10-13

Similar Documents

Publication Publication Date Title
WO2013085550A3 (en) V1v2 immunogens
MX352324B (en) Multivalent synthetic nanocarrier vaccines.
WO2013006688A3 (en) N-terminal deleted gp120 immunogens
WO2013016468A3 (en) Compositions and methods for improving potency and breadth or hiv antibodies
WO2011046623A3 (en) Hiv-1 antibodies
WO2013021279A3 (en) Highly galactosylated antibodies
WO2011036564A3 (en) Hyperblebbing shigella strains
WO2011106100A3 (en) Method of inducing the production of protective anti-hiv-1 antibodies
WO2012027365A3 (en) Targeted multi-epitope dosage forms for induction of an immune response to antigens
WO2011142970A3 (en) Her2 nucleic acid aptamers
WO2010019262A3 (en) Polyvalent vaccine
WO2013034979A3 (en) Crystalline forms of cabazitaxel
WO2012016683A3 (en) Oral dosage form of pregabalin
WO2013090644A3 (en) Anti-hiv antibodies having increased potency and breadth
WO2011109511A3 (en) Novel hiv-1 envelope glycoprotein
GB201303865D0 (en) Pharmaceutical composition and method of inhibiting of production or amplifyingelimination of P24 protein
WO2012047267A3 (en) Polyvalent immunogen
MX2014014682A (en) Stabilized gp120.
HK1200329A1 (en) Truncated hiv envelope proteins (env), methods and compositions related thereto hiv (env)
WO2012136898A3 (en) Novel cutinases, their production and uses
WO2012037116A3 (en) Genetic variations associated with common variable immunodeficiency (cvid) and methods of use thereof
MY158910A (en) Surface modified silicic acid semi-gels
EP2928492A4 (en) Hiv-1 envelope proteins and fragments thereof that possess epitopes recognized by broadly neutralizing antibodies
WO2013052095A3 (en) Vaccine
ZA201307069B (en) Combined cell based gp96-ig-siv/hiv, recombinant gp120 protein vaccination for protection from siv/hiv

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11766282

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11766282

Country of ref document: EP

Kind code of ref document: A2